The human epidermal receptor-2 (HER-2) is overexpressed or amplified in 15% to 25% of
breast cancers. Determination of HER-2 tumor status offers clinically useful information, as it …

Epidermal growth factor receptor (EGFR) serves as a co-target for dual/pan-EGFR-inhibitors
in breast cancer. Findings suggest that EGFR and EGFR-ligands are involved in resistance …

Background The aim of the present study was to investigate the efficacy of adjuvant dose-
dense sequential chemotherapy with epirubicin, paclitaxel, and CMF in subgroups of …

Introduction Neoadjuvant chemotherapy has become the standard of care for the diverse
population of women diagnosed with locally advanced breast cancer. Serum biomarker …

Purpose: Chemotherapy can be an integral component of the adjuvant management
strategy for women with early stage breast cancer. To date, no tool is available to predict or …

Oncoproteomics is playing an increasingly important role in the diagnosis and management
of cancer as well as in the development of personalized treatment of cancer. Innovative …

Abstract HER-2/neu, also known as c-erbB-2/neu, is an oncogene located in chromosome
17 which encodes HER-2/neu, a transmembrane protein belonging to the EGFR family. The …

Background: Ultraviolet B (UVB) is the most damaging component of sunlight. It rapidly
activates the epidermal growth factor receptor (EGFR) and generates reactive oxygen …

This paper presents the realization of a portable, point-of-care and multi-target
immunosensing lab-on-a-chip (LOC). The chip utilizes a novel on-chip actuating mechanism …

Background: This study aimed to identify predictors of response to anthracycline-based
chemotherapy (5-fluoro-uracil, epirubicin, cyclophosphamide (FEC)) in locally advanced …